Clinical Trial Planning in Pompe Disease

庞贝病的临床试验计划

基本信息

批准号：
8502230
负责人：
Dwight D Koeberl
金额：
$ 26.69万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-03-13 至 2014-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8502230
关键词：
Acids Address Adult Adverse event Advisory Committees Antibody Formation Budgets Clinical Clinical Protocols Clinical Research Clinical Trials Data Dependence Development Disease Electronic Mail Foundations Future Glycogen storage disease type II Goals Health Benefit Human Immune Tolerance Immune response Infusion procedures Institutes Institutional Review Boards Investigational Drugs Investigational New Drug Application Lead Liver Mediating Medical Modeling Monitor Mus Myopathy Outcome Participant Patients Pharmacology and Toxicology Phase Phase I Clinical Trials Phase I/II Trial Process Protocols documentation Public Health Publications Recombinant DNA Recombinants Recruitment Activity Reporting Research Research Infrastructure Research Institute Research Personnel Risk Safety Site Smooth Muscle Source Striated Muscles Surveys System TimeLine Translations United States Food and Drug Administration Writing adeno-associated viral vector base clinically significant cohort eligible participant enzyme replacement therapy gene therapy gene therapy clinical trial glucosidase improved infancy institutional biosafety committee meetings mortality pre-clinical public health relevance research study

项目摘要

DESCRIPTION (provided by applicant): Pompe disease (glycogen storage disease type II; acid maltase deficiency; MIM 232300) is a myopathy that results from acid a-glucosidase (GAA) deficiency in striated and smooth muscle. The limitations of enzyme replacement therapy with recombinant human GAA have prompted the preclinical development of gene therapy for Pompe disease. The goal of this application is to launch a clinical trial of gene therapy in adults with Pompe disease. Activities will include establishing multiple sites to recruit adequate numbers of subjects for Phase I and II clinical trials; develop a study protocol; prepare the institutional review board protocol; obtain institutional biosafety committee approval; develop a recruitment plan for potential participants; prepare all documents for the filing of an investigational new drug (IND) application; develop a safety monitoring plan to minimize risk, develop a system for reporting adverse events; and to formulate a budget and timeline for conduct and completion of the clinical trial. This clinical trial planning project will lead to an ND being submitted to the Food and Drug Administration for gene therapy in Pompe disease.

描述（由申请人提供）：蓬松疾病（II型糖原储存疾病；酸性麦芽糖酶缺乏症； MIM 232300）是一种肌病，是由酸A-葡萄糖苷酶（GAA）缺乏症状和平滑肌中的肌病。重组人GAA的酶替代疗法的局限性促使基因疗法促蓬松疾病的临床前开发。该应用的目的是在成人中发起基因治疗的临床试验患有庞贝疾病。活动将包括建立多个地点，以招募足够数量的I期和II期临床试验的受试者；制定研究方案；准备机构审查委员会协议；获得机构生物安全委员会批准；为潜在参与者制定招聘计划；准备所有文件以提交研究新药（IND）申请；制定安全监控计划，以最大程度地降低风险，开发用于报告不良事件的系统；并制定预算和时间表，以进行临床试验的行为和完成。该临床试验计划项目将导致ND提交给食品药物管理局的庞贝疾病基因治疗。